2024
Insights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022
da Silva L, Alcantara L, Fonseca V, Frias D, Zardin M, de Castro Lichs G, Esposito A, Xavier J, Fritsch H, Lima M, de Oliveira C, de Arruda L, de Mello Almeida Maziero L, Barretos E, Oshiro P, Menezes E, de Freitas Cardoso L, Lemos E, Lourenço J, de Albuquerque C, do Carmo Said R, Rosewell A, Demarchi L, Croda J, Giovanetti M, Gonçalves C. Insights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022. Viruses 2024, 16: 1143. PMID: 39066305, PMCID: PMC11281713, DOI: 10.3390/v16071143.Peer-Reviewed Original ResearchConceptsNext-generation sequencingPrison populationIncarcerated populationsOvercrowded cellsGenome sequenceGenomic characteristicsPrisonGenomic surveillanceEnclosed populationMato GrossoAverage coverageIsolation protocolSARS-CoV-2RT-qPCR testSARS-CoV-2 surveillanceRT-qPCRSequenceFrequent transferEpidemiological monitoringLimited healthcare accessGenomeCellsOmicron variant
2023
Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area
de Oliveira L, Dos Santos Barbosa M, Leite Torres A, Croda M, Oliveira da Silva B, Dos Santos P, Rossoni R, Machado L, Croda J, Maymone Gonçalves C, Marques M, da Silva Ferreira T, Sardi S, Campos G, de Almeida G, Alves Gomes M, Marchioro S, Simionatto S. Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area. PLOS ONE 2023, 18: e0295211. PMID: 38134187, PMCID: PMC10745159, DOI: 10.1371/journal.pone.0295211.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayCoronaVac inactivated vaccinesSARS-CoV-2SARS-CoV-2 infectionEnzyme-linked immunosorbent assay methodMedian ageSARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2Asymptomatic individualsRapid testSeropositivity rateBlood samplesEthnic groupsElevated seroprevalenceImmunosorbent assaySeroprevalence of SARS-CoV-2 infectionSARS-CoV-2 rapid testSeropositivityAntibodiesVulnerable ethnic groupsSeroprevalenceGenomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil
de Oliveira L, de Rezende I, Navarini V, Marchioro S, Torres A, Croda J, Croda M, Gonçalves C, Xavier J, de Castro E, Lima M, Iani F, Adelino T, Aburjaile F, Demarchi L, Taira D, Zardin M, Fonseca V, Giovanetti M, Andrews J, Alcantara L, Simionatto S. Genomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil. Frontiers In Public Health 2023, 11: 1195779. PMID: 37965526, PMCID: PMC10641392, DOI: 10.3389/fpubh.2023.1195779.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineagesIntroduction eventsCharacterization of SARS-CoV-2Nanopore sequencing platformSARS-CoV-2 positive samplesMultiple SARS-CoV-2 variantsMultiple introduction eventsPhylogenetic reconstructionPhylogenetic dataGenome sequenceSequencing platformsGenomic characterizationSARS-CoV-2Genomic surveillanceSARS-CoV-2 variantsLineagesMato GrossoMortality rateViral dynamicsIndigenous populationCo-circulationPrevalence of malesMidwestern BrazilPositive samplesIndigenous mobilizationPan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa A, Chebabo A, Starling C, Pérez C, Cunha C, de Luna D, Nunes E, Zambrano G, Ferreira J, Croda J, Falavigna M, Gomes-da-Silva M, Thormann M, Cimerman S, Parahiba S, Tanni S, Bernardo W, Rodriguez-Morales A. Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals Of Clinical Microbiology And Antimicrobials 2023, 22: 67. PMID: 37550690, PMCID: PMC10408214, DOI: 10.1186/s12941-023-00623-w.Peer-Reviewed Original ResearchConceptsUse of hydroxychloroquineInfectious diseasesCOVID-19Treatment of outpatientsSARS-CoV-2/COVIDSevere COVID-19Evidence-based guidelinesPan American AssociationGuideline development processLack of benefitEvidence-based medicineAdverse eventsMechanical ventilationClinical manifestationsTherapeutic optionsPharmacological treatmentCOVID-19 episodeInpatient settingAmerican guidelinesGRADE systemSystematic reviewStrong recommendationsProphylaxisOutpatientsDiseaseUnveiling the Impact of the Omicron Variant: Insights from Genomic Surveillance in Mato Grosso do Sul, Midwest Brazil
de Mello Almeida Maziero L, Giovanetti M, Fonseca V, Zardin M, de Castro Lichs G, de Rezende Romera G, Tsuha D, Frias D, Escandolhero V, Demarchi L, Castilho L, Barbosa K, Tebet D, Xavier J, Fritsch H, Lima M, de Oliveira C, Santos E, Kashima S, do Carmo Said R, Rosewell A, Croda J, Alcantara L, Gonçalves C. Unveiling the Impact of the Omicron Variant: Insights from Genomic Surveillance in Mato Grosso do Sul, Midwest Brazil. Viruses 2023, 15: 1604. PMID: 37515290, PMCID: PMC10386548, DOI: 10.3390/v15071604.Peer-Reviewed Original ResearchConceptsGenomic surveillanceWhole-genome sequencingMultiple introduction eventsGenome sequencePublic health interventionsGenomic dataGenomic monitoringIntroduction eventsPublic health responseGenomic landscapeDispersal dynamicsPhylodynamic analysesPublic health laboratoriesHealth interventionsMato GrossoHealth responseTransmissible variantsSignificant burdenCentral Public Health LaboratoryOmicron variantVariantsHealth laboratoriesSequenceMidwest region of BrazilViral strainsImpact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C, Pittet L, Jamieson T, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Curtis N, Croda J. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers In Immunology 2023, 14: 1172851. PMID: 37465688, PMCID: PMC10352084, DOI: 10.3389/fimmu.2023.1172851.Peer-Reviewed Original ResearchConceptsRecent BCG vaccinationBCG vaccinationAntibody responseVaccine platformAnti-spike IgG responseCOVID-19 vaccinationCOVID-19 vaccineCoronaVac vaccinationPrior vaccinationVaccine responsesIgG responsesSecond doseIgG antibodiesHealthcare workersVaccinationChAdOx1CoronaVacCOVID-19VaccineMultiple factorsResponsePlaceboDoseTrialsAntibodiesExploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges
Croda J. Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges. The Lancet Infectious Diseases 2023, 23: 1099-1100. PMID: 37352881, PMCID: PMC10281640, DOI: 10.1016/s1473-3099(23)00363-8.Peer-Reviewed Original ResearchRandomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers
Pittet L, Messina N, Orsini F, Moore C, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollman T, Lacerda M, Lee K, Lucas M, Lynn D, Manning L, Marshall H, McDonald E, Munns C, Nicholson S, O’Connell A, de Oliveira R, Perlen S, Perrett K, Prat-Aymerich C, Richmond P, Rodriguez-Baño J, dos Santos G, da Silva P, Teo J, Villanueva P, Warris A, Wood N, Davidson A, Curtis N. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. New England Journal Of Medicine 2023, 388: 1582-1596. PMID: 37099341, PMCID: PMC10497190, DOI: 10.1056/nejmoa2212616.Peer-Reviewed Original ResearchConceptsBacille Calmette-GuerinModified intention-to-treat populationIntention-to-treat populationSevere COVID-19Placebo groupSymptomatic COVID-19Health care workersBCG-DenmarkPlacebo-controlled trialCare workersRisk of severe COVID-19Double-blindSaline placeboRisk of symptomatic COVID-19Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Negative testRandomized trialsRespiratory syndrome coronavirus 2Hazard ratioPrimary outcomeBCG vaccinationTrial definitionSyndrome coronavirus 2Risk difference
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of testEffectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original ResearchSerum biomarkers associated with SARS-CoV-2 severity
de Morais Batista F, Puga M, da Silva P, Oliveira R, dos Santos P, da Silva B, Tatara M, Tsuha D, dos Santos Pires M, Gonçalves C, Pessoa e Silva R, Ferreira N, de Barros Albuquerque A, da Silva Duarte G, Consolaro M, Negrão F, Ferrari I, de Goes Cavalcanti L, Trinta K, Ribeiro G, de Melo Rêgo M, Boyton R, Siqueira A, Altmann D, Croda J. Serum biomarkers associated with SARS-CoV-2 severity. Scientific Reports 2022, 12: 15999. PMID: 36163447, PMCID: PMC9511452, DOI: 10.1038/s41598-022-20062-5.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSevere casesSARS-CoV-2 severityCytokine/chemokine productionImmune response profileBiological marker levelsSARS-CoV-2GDF-15Clinical courseAcute phaseChemokine productionD-dimerSICAM-1Marker levelsSerum biomarkersHeart diseasePrognostic markerCardiovascular diseaseGroup C.Angiogenesis markersGroup SPrognostic signatureGroup MP-selectinDisease severityGenomic epidemiology of the SARS-CoV-2 epidemic in Brazil
Giovanetti M, Slavov S, Fonseca V, Wilkinson E, Tegally H, Patané J, Viala V, San E, Rodrigues E, Santos E, Aburjaile F, Xavier J, Fritsch H, Adelino T, Pereira F, Leal A, Iani F, de Carvalho Pereira G, Vazquez C, Sanabria G, Oliveira E, Demarchi L, Croda J, dos Santos Bezerra R, Paola Oliveira de Lima L, Martins A, Renata dos Santos Barros C, Marqueze E, de Souza Todao Bernardino J, Moretti D, Brassaloti R, de Lello Rocha Campos Cassano R, Mariani P, Kitajima J, Santos B, Proto-Siqueira R, Cantarelli V, Tosta S, Nardy V, Reboredo de Oliveira da Silva L, Gómez M, Lima J, Ribeiro A, Guimarães N, Watanabe L, Barbosa Da Silva L, da Silva Ferreira R, da Penha M, Ortega M, de la Fuente A, Villalba S, Torales J, Gamarra M, Aquino C, Figueredo G, Fava W, Motta-Castro A, Venturini J, do Vale Leone de Oliveira S, Gonçalves C, do Carmo Debur Rossa M, Becker G, Giacomini M, Marques N, Riediger I, Raboni S, Mattoso G, Cataneo A, Zanluca C, Duarte dos Santos C, Assato P, Allan da Silva da Costa F, Poleti M, Lesbon J, Mattos E, Banho C, Sacchetto L, Moraes M, Grotto R, Souza-Neto J, Nogueira M, Fukumasu H, Coutinho L, Calado R, Neto R, Bispo de Filippis A, Venancio da Cunha R, Freitas C, Peterka C, de Fátima Rangel Fernandes C, Navegantes W, do Carmo Said R, Campelo de A e Melo C, Almiron M, Lourenço J, de Oliveira T, Holmes E, Haddad R, Sampaio S, Elias M, Kashima S, Junior de Alcantara L, Covas D. Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil. Nature Microbiology 2022, 7: 1490-1500. PMID: 35982313, PMCID: PMC9417986, DOI: 10.1038/s41564-022-01191-z.Peer-Reviewed Original ResearchConceptsVariants of concernSARS-CoV-2 variantsLocal transmission clustersSARS-CoV-2 epidemicSARS-CoV-2COVID-19 casesTransmission clustersVirus transmission dynamicsSustained transmissionMultiple importationsMultiple viral lineagesGenomic epidemiologyGenomic surveillanceReal-time spreadTransmission dynamicsEpidemicViral lineagesHigher numberPandemicRestriction measuresEpidemiologyVariantsAre we near the end of the pandemic?
Maciel E, Oliveira W, Siqueira P, Croda J. Are we near the end of the pandemic? Revista Da Sociedade Brasileira De Medicina Tropical 2022, 55: e0233-2022. PMID: 35613223, PMCID: PMC9131776, DOI: 10.1590/0037-8682-0233-2022.Peer-Reviewed Original ResearchCoronavirus disease COVID-19 pandemic and the Declaration of Public Health Emergency in Brazil: administrative and epidemiological aspects
de Oliveira W, de Góes Cavalcanti L, Croda J. Coronavirus disease COVID-19 pandemic and the Declaration of Public Health Emergency in Brazil: administrative and epidemiological aspects. Revista Da Sociedade Brasileira De Medicina Tropical 2022, 55: e0227-2022. PMID: 35613222, PMCID: PMC9131777, DOI: 10.1590/0037-8682-0227-2022.Peer-Reviewed Original Research
2021
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
Croda J, Ranzani O. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. The Lancet Infectious Diseases 2021, 22: 430-432. PMID: 34890538, PMCID: PMC8651253, DOI: 10.1016/s1473-3099(21)00696-4.Peer-Reviewed Original ResearchBCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)
Pittet L, Messina N, Gardiner K, Orsini F, Abruzzo V, Bannister S, Bonten M, Campbell J, Croda J, Dalcolmo M, Elia S, Germano S, Goodall C, Gwee A, Jamieson T, Jardim B, Kollmann T, Lacerda M, Lee K, Legge D, Lucas M, Lynn D, McDonald E, Manning L, Munns C, Perrett K, Aymerich C, Richmond P, Shann F, Sudbury E, Villanueva P, Wood N, Lieschke K, Subbarao K, Davidson A, Curtis N, Abreu C, Abruzzo V, Addlem L, Agius S, Barbosa A, Alamrousi A, Santos A, Al-Hindawi Y, Da Silveira S, Cruz L, Anderson J, Anthony C, Pereira A, Almajano F, Arnold A, Arrowsmith B, Azzopardi K, Marti C, Bahaduri T, Bannister S, Barney S, Barrera L, Barriocanal A, Barros D, Barry S, Bartlett A, Muranaka L, Baulman T, Bealing M, Beardsley J, Gutierrez A, Bell J, Benson S, Bennett-Wood V, Bergant N, Barbosa F, Bijllaardt W, Bimboese P, Andrade C, Blake S, Blauwendraat K, Boersma W, Garcia P, Bonnici R, Bonten M, Boon A, Bourke A, Bowes K, Brasil L, Brophy C, Botten R, Buchanan S, Bucholc J, Burns A, Burrell E, Bustos N, Byrne B, Byrne A, Calbo E, Montes J, Camesella B, Campbell J, Cangas A, Carlin J, Roque M, Diogo R, Carvalho E, Casas I, Castro E, Castro R, Catterick H, Escobar R, Chan J, Cheah J, Chern T, Chengodu T, Ciaverella M, Clark S, Espindola M, Cobbledick A, Colaco C, Collopy S, Comella P, Corbett M, Castro G, Costa E, Coya R, Crawford N, Croda J, Cruz A, Curtis N, Cushnahan J, Czajko A, da Silva R, Daitiri B, Dalcolmo M, Dalton K, Dao A, Davidson A, Dawe P, Dawson D, Costa M, De La Cruz K, de Serna A, de Morais Batista F, de Oliveira A, del Rey Morillo R, Desylva M, Dijkstra H, Dixon R, Lopez M, Dominguez J, Doran C, Castellano A, Dos Santos G, Lencina J, Silva D, Douglas M, Dunn R, Dunn A, Dunnill J, Eden G, Edmund H, Eiffler N, Elborough H, Elia S, Elkington O, England M, Ayala W, Esteve M, Evans N, Evans S, Ewe K, Álvarez M, Fahey K, Fairweather J, Faustman D, Silva E, Fernandez M, Fidler G, Filius P, Finn A, Finucane C, Firth S, Fletcher E, Flynn C, Flynn L, Fouracre L, Fowler S, Freitas T, Furtado A, Oliveira M, Santos A, Gonçalves L, Galletta L, Gama L, Gamage D, Ganpat R, García C, Croda M, Gardiner K, Gardiner E, Gell G, Oliveira A, Germano S, Gibbons M, Gibson C, Gifford A, Poderos T, Ginsberg A, Gisolf J, Gladanac B, Glenn P, Godinho V, Santos M, Goikoetxea J, Goldenberg T, Gomes A, Marcos S, Rico C, Goodall C, Gordon V, Greven F, Capella A, Griffith L, Guo C, Campos D, Cuadra M, Gwee A, Hall R, Hall L, Hamilton K, Hannan M, Harbech H, Harding A, Haker N, Harrison R, Hassing R, Rosa T, Haywood Z, Heath C, Henare N, Andrade P, Herrmann S, Hill E, Hilton S, Huijbens D, Hutton H, James J, Jamieson T, Janssen A, Jardim B, Jardim T, Jarvis L, Jenkins N, Jones J, Jones J, Jones K, Jorge L, Vilegas M, Joshi S, Joyce R, Junior J, Kandasamy R, Karunanayake A, Karuppasamy H, Keeble T, Kent J, Kloeg P, Kluytmans J, Knight B, Kollmann T, Korman T, Krastev A, Krieg M, La N, Lacerda M, Lacoma A, Lagunday R, Lalich D, Latkovic E, Latorre I, Leandro P, Lee K, Legge D, Lemmers T, Leurink T, Lieschke K, Lim K, Lockhart G, Bogéa C, Santos K, Marques R, Lucas M, Lynn D, Lynn M, Freitas M, Ma N, Macalister S, Machado C, Ramos M, Machingaifa F, Maia I, Maia B, Malley R, Manning L, Manton S, Carrerero J, Barriocanal A, Alves C, Pereira R, Arruda B, Marins A, Marshall H, Markow A, Martin C, Almeida K, Mather W, Mathers M, Gomes F, Tadokoro M, Mazarakis N, Mazurega K, McAlister S, McAndrews A, McDonald E, McDonald F, McElroy R, McMillan M, McMullan B, McPhate N, Mead L, Meehan A, Meek B, Melo R, Mena G, Mesquita D, Messina N, Mezzetti I, Vieira H, Miller S, Mitchell K, Mitchell M, Mojeed J, Molenaar K, Molina G, Molina B, Montgomery L, Moore C, Moore J, Moorlag S, Morawakage T, Moss J, Moyle W, Mulholland K, Munns C, Nascimento E, Navarrette N, Netea M, Neves J, Newman G, Ngien B, Nguyen J, Nguyen K, Noonan F, Norton W, O’Donnell M, O’Bryan J, O’Connell A, Odoi S, O’Donnell L, Oliveira R, Oliveira M, Oliveira T, Oliveira I, Olivier N, Olivio L, Ong B, Ong J, Ong J, Onysk J, Ooi I, Oppedisano F, Orsini F, Ortika B, Group O, Otsuka A, Overton K, Owens R, Paes R, Palasanthiran P, Jiménez V, Pandine G, Parkin K, Hernandez A, Paternotte N, Paterson D, Souza A, Pelayo L, Pell C, Pelser S, Pereira H, Pereira G, Perez G, Perez C, Porcuna T, Perlen S, Perrett K, Floy A, Pitkin S, Pittet L, Pon R, Calderón I, Post J, Power C, Prado C, Prajitno E, Prat-Aymerich C, Preijers L, Puga M, Queiroz E, Quinn L, Rak A, Figueiredo L, de Arellano E, Ramos P, Oliveira K, Ren J, Reynolds S, Rhodes S, Santos C, Richards C, Richmond P, Richmond H, Souza A, Rocha J, Rodrigues T, Rodrigues L, Rodrigues B, Fernandes I, Rodríguez-Baño J, Roescher N, Rogers S, Rol A, Romme J, Rosell A, Font M, Sallent S, Sacca D, Sampaio V, Sanchez N, Sanchez B, Santos D, Santos T, Sartim A, Sastry A, Sawka A, Schultz N, Seamark C, Seamark D, Septer-Bijleveld E, Serrano R, Shann F, Sharma K, Shave M, Shen L, Sidaway-Lee K, Baena A, Silva R, Silva J, Silva E, Simão M, Singh R, Siqueira M, Chaves M, Sondag T, Sooriyarachchi E, Sousa A, Spry L, Statton S, Steer A, Santos D, Sterling K, Steve L, Stevens L, Stevens N, Stewart C, Stiglmayer L, Stooper L, Studham J, Subbarao K, Sudbury E, Suiker A, Symons L, Taks E, Tan N, Meireles B, Riele M, Oever J, Lima G, Heine R, Angelo J, Thomson H, Toh R, Trindade A, Tripp H, Tristán E, Troeman D, Truelove A, Tsuha D, Uffing M, Val F, Valero O, Valls E, van Ven C, Van Heuvel L, van Veen S, van Waal M, van Leusen J, van Mook L, van Onzenoort H, van Opdorp M, van Rijen M, van Sluis N, Vasconcelos A, Vega N, Velagapudi S, Vennells L, Venton T, Verheij H, Verhoeven P, Ramos C, Silva P, Vidal S, Vieira P, Oliveira M, Ortega R, Villanueva P, Villar R, Vlahos A, Wadia U, Walker M, Wall K, Wallace R, Waring J, Warren R, Warris A, Watts E, Wearing-Smith M, Webber-Rookes D, Wedderburn J, Wee-Hee A, Wesselingh S, Teo J, Whale B, Williams P, Wolters B, Wood N, Xie I, Younes A, Young A, Batista F, Zhou C, Zwart V, Goodchild L. BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial). BMJ Open 2021, 11: e052101. PMID: 34711598, PMCID: PMC8557250, DOI: 10.1136/bmjopen-2021-052101.Peer-Reviewed Original ResearchConceptsBCG vaccinationHealthcare workersSARS-CoV-2 infectionCOVID-19Multicentre phase IIISevere COVID-19Episodes of illnessPeer-reviewed open access journalsSARS-CoV-2Respiratory illnessSafety profileClinical detailsWork absenteeismImmune responseBlood samplesVaccinationImmune systemInexpensive interventionSecondary objectiveUnrelated pathogensPhase IIIOff-target effectsImmunological analysisIllnessGovernance approvalRisk Factors for Death Among 120,804 Hospitalized Patients with Confirmed COVID-19 in São Paulo, Brazil
da Silva P, de Oliveira S, Escalante J, Almiron M, Tsuha D, Sato H, Menezes P, de Paula R, D’Agostini T, Croda J. Risk Factors for Death Among 120,804 Hospitalized Patients with Confirmed COVID-19 in São Paulo, Brazil. American Journal Of Tropical Medicine And Hygiene 2021, 105: 88-92. PMID: 34061773, PMCID: PMC8274770, DOI: 10.4269/ajtmh.20-1598.Peer-Reviewed Original ResearchConceptsCOVID-19Confirmed COVID-19Characteristics of patientsChronic lung diseaseIntensive care unitChronic cardiovascular diseaseChronic neurological diseaseMore comorbiditiesClinical characteristicsDiabetes mellitusMedian ageCare unitLung diseaseRisk factorsCardiovascular diseaseHigh riskSevere casesElderly individualsPatientsNeurological diseasesSurvival analysisCoronavirus diseaseDiseaseSão PauloDeath
2020
Reinfection of COVID‐19 after 3 months with a distinct and more aggressive clinical presentation: Case report
de Araujo Torres D, do Carmo Bueno Ribeiro L, de Freitas Linhares Riello A, Horovitz D, Pinto L, Croda J. Reinfection of COVID‐19 after 3 months with a distinct and more aggressive clinical presentation: Case report. Journal Of Medical Virology 2020, 93: 1857-1859. PMID: 33112002, DOI: 10.1002/jmv.26637.Peer-Reviewed Original ResearchSerial interval distribution of SARS-CoV-2 infection in Brazil
Prete C, Buss L, Dighe A, Porto V, da Silva Candido D, Ghilardi F, Pybus O, de Oliveira W, Croda J, Sabino E, Faria N, Donnelly C, Nascimento V. Serial interval distribution of SARS-CoV-2 infection in Brazil. Journal Of Travel Medicine 2020, 28: taaa115. PMID: 32710618, PMCID: PMC7454808, DOI: 10.1093/jtm/taaa115.Peer-Reviewed Original ResearchEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapy